Events

2017 News Releases



Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
03/07/17Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update
Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., March 7, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2016. Recent Achievements In August and October 2016, Rigel reported results from the three FIT Phase 3 clinical studies of fostamatinib in immune thrombocytopenia (ITP), which showed a consistent fostamatinib response rate. In January 2017, ... 
 Printer Friendly Version
02/28/17Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2016 financial results after market close on Tuesday, March 7, 2017.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or... 
 Printer Friendly Version
02/03/17Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the closing of its previously announced underwritten public offering of 23,000,000 shares of its common stock at a price to the public of $2.00 per share, which includes 3,000,000 additional shares of common stock issued upon the exercise in full of the underwriters' option to purchase additional shares.  The gross proceeds to Rigel from this offering are $46,000,000, before deduc... 
 Printer Friendly Version
01/31/17Rigel Announces Pricing Of Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the pricing of its previously announced underwritten public offering of 20,000,000 shares of its common stock, offered at a price of $2.00 per share to the public.  The gross proceeds to Rigel from this offering are expected to be approximately $40,000,000, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Rigel.  All of th... 
 Printer Friendly Version
01/30/17Rigel Announces Proposed Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering are to be sold by Rigel, with the proceeds to be u... 
 Printer Friendly Version
01/30/17Fostamatinib Study Results Continue to Trend Positive
Rigel Provides Update in ITP SOUTH SAN FRANCISCO, Calif., Jan. 30, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced updates from the clinical program of fostamatinib in patients with chronic immune thrombocytopenic purpura (ITP). Previously released results from the FIT Phase 3 clinical studies (047, 048) of fostamatinib in chronic ITP demonstrated that patients who responded to fostamatinib have a timely, robust, and sustained response to treatment.  As of ... 
 Printer Friendly Version
01/05/17Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy
Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco SOUTH SAN FRANCISCO, Calif., Jan. 5, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financial overview at the upcoming 35th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2017, at 2pm PST (see webcast details below)... 
 Printer Friendly Version